Viz.ai Appoints Hypertrophic Cardiomyopathy Medical Advisory Board to Advance Innovation

Leading experts to shape the future of Viz.ai’s HCM strategy and platform

SAN FRANCISCO--(BUSINESS WIRE)--#ai--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Hypertrophic Cardiomyopathy (HCM) Medical Advisory Board to assist the company in the development of strategy and products to support cardiologists and improve patient care. The board consists of leading cardiology experts with diverse roles and experiences.

“The role of artificial intelligence in cardiology is growing exponentially and the creation of the HCM Medical Advisory Board will ensure the Viz.ai’s cardiovascular program will be shaped with the latest insights in the field,” said Matthew Martinez, MD, Director of Sports Cardiology and HCM, Atlantic Health System, and co-chair of the HCM Medical Advisory Board. “Working alongside other HCM experts with clinical experience using artificial intelligence, I’m eager to contribute to innovative developments that will improve patient outcomes.”

“I’m honored to share my expertise to enhance Viz.ai’s approach toward innovation,” said Roselle Abraham, MD, Director of the Hypertrophic Cardiomyopathy Clinic and Cardiologist, UCSF and co-chair of the HCM Medical Advisory Board. “I look forward to the rich dialogue of this accomplished team to explore ideas that will increase patient access to life-saving therapies.”

The board will assist the Viz team by informing its HCM strategy and research and development activities. Members will assess the impact of Viz HCM* and the Viz Cardio Suite, identify clinical need for new features and modes of implementation, verify effectiveness of new capabilities, and ensure that sound scientific evidence supports projects. Additionally, the board will provide strategic advice regarding emerging science and therapeutic trends. Viz recently submitted a de novo request to the FDA for the Viz HCM algorithm as a Software-as-a-Medical-Device (SaMD), and the filing has been accepted by the agency for review.

“The deep expertise of the HCM Advisory Board will drive the development of products that support cardiologists in their work and enhance patient outcomes,” said Jayme Strauss, chief clinical officer at Viz.ai. “We are immensely grateful for the expertise, time, and support of our board members and proud to partner with them on this transformative endeavor.”

*Viz HCM is not available for sale. Investigational use only.

About Viz.ai, Inc.

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

Laurie Masonson
laurie.masonson@finnpartners.com